Comparitive Efficacy of Selected Modes of Inhibiting the Renin Angiotensin System on the Development of Hypercholesterolemia-Induced Atherosclerosis

Grants and Contracts Details

StatusFinished
Effective start/end date7/1/086/30/11

Funding

  • Novartis (domestic): $232,701.00